Enzo Biochem, Inc. (NYSE:ENZ) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,470,000 shares, an increase of 11.8% from the June 30th total of 2,210,000 shares. Based on an average trading volume of 1,140,000 shares, the short-interest ratio is currently 2.2 days. Approximately 5.6% of the company’s shares are short sold.

Shares of ENZ traded down $0.09 during midday trading on Friday, hitting $2.38. The stock had a trading volume of 1,038,810 shares, compared to its average volume of 2,025,024. Enzo Biochem has a 1 year low of $1.56 and a 1 year high of $4.85. The company has a current ratio of 2.27, a quick ratio of 2.02 and a debt-to-equity ratio of 0.35. The stock’s 50 day moving average is $2.43 and its 200 day moving average is $2.53.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings results on Monday, June 8th. The medical research company reported ($0.17) EPS for the quarter. Enzo Biochem had a negative return on equity of 36.23% and a negative net margin of 39.50%. The company had revenue of $16.90 million during the quarter.

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in Enzo Biochem by 32.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 48,183 shares of the medical research company’s stock worth $126,000 after buying an additional 11,780 shares during the last quarter. Invesco Ltd. raised its position in Enzo Biochem by 19.4% during the 1st quarter. Invesco Ltd. now owns 72,651 shares of the medical research company’s stock worth $184,000 after buying an additional 11,781 shares during the last quarter. Geode Capital Management LLC raised its position in Enzo Biochem by 8.9% during the 1st quarter. Geode Capital Management LLC now owns 559,743 shares of the medical research company’s stock worth $1,416,000 after buying an additional 45,951 shares during the last quarter. Baird Financial Group Inc. purchased a new position in Enzo Biochem during the 1st quarter worth approximately $38,000. Finally, SG Americas Securities LLC purchased a new position in Enzo Biochem during the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 60.07% of the company’s stock.

Separately, ValuEngine upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating in a research report on Tuesday, June 9th.

Enzo Biochem Company Profile

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Featured Story: How do analysts define an oversold condition?

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.